February 13th 2023
Although trilaciclib appears to reduce neutropenia following treatment with FOLFOXIRI and bevacizumab in patients with metastatic colorectal cancer, the phase 3 PRESERVE 1 trial will be stopped due to a lack of responses.
January 23rd 2023
Considering a Patient with Colorectal Cancer for Adjuvant ChemotherapyFebruary 10th 2023
Aparna Parikh, MD, MS, details when she would recommend adjuvant chemotherapy to patients with similar presentations of colorectal cancer.
Patient Scenario: A 64-Year-Old Man with Stage II Colon CancerFebruary 10th 2023
Tanios S. Bekaii-Saab, MD, presents a patient scenario of a 64-year-old man with stage 2 (pT3N0) colon cancer to the panel for discussion.
ctDNA May Be Ideal Biomarker for Early Response Assessment in Advanced Colorectal CancerJanuary 22nd 2023
Molecular responders by G360 response algorithm with advanced colorectal cancer appear to have significantly lengthened time on treatment and overall survival with all regimens vs patients who did not respond.
FDA Grants Accelerated Approval to Tucatinib Plus Trastuzumab for Advanced HER2+ Metastatic CRCJanuary 19th 2023
The FDA based its accelerated approval of tucatinib and trastuzumab combination therapy for HER2-positive metastatic colorectal cancer on results from the phase 2 MOUNTAINEER trial.
Advice on HER2+ Metastatic Colorectal Cancer for Patients and CaregiversJanuary 9th 2023
Elle Charnisky, a patient with HER2+ metastatic colorectal cancer, and Deanne Griffie, a nurse practitioner, share advice for patients and caregivers living with HER2+ mCRC.
Managing Toxicities with Tucatinib in Patients with HER2+ mCRCJanuary 9th 2023
Deanna Griffie, MSN, AGNP-BC, and Tanios Bekaii-Saab, MD, explain how they manage the toxicities of tucatinib in patients with HER2+ mCRC, and how they educate patients on what to expect.
Metastatic CRC: Unmet Needs and Future Directions in CareJanuary 4th 2023
Closing out their review of the metastatic colorectal cancer treatment paradigm, expert panelists consider how the treatment armamentarium will continue to evolve.
FRESCO-2 Trial: Role of Fruquitinib in Refractory Metastatic CRCJanuary 4th 2023
Focused discussion on the FRESCO-2 trial, which analyzed use of fruquitinib in the refractory setting of metastatic colorectal cancer.
Role of Immunotherapies in Microsatellite Stable Metastatic CRCDecember 28th 2022
Shared insight on the potential role for immunotherapeutic agents in the setting of microsatellite stable metastatic colorectal cancer.
Updates in the Management of KRASG12C-Mutated Metastatic CRCDecember 28th 2022
Centering discussion on KRASG12C-mutated metastatic colorectal cancer, panelists highlight recent clinical studies of targeted agents in this subset of disease.
FDA Grants Breakthrough Therapy Designation to Adagrasib/Cetuximab for KRAS G12C+ CRCDecember 22nd 2022
The FDA granted breakthrough therapy designation to adagrasib plus cetuximab for patients with KRAS G12C–mutated advanced colorectal cancer based on findings from the phase 1b cohort of the KRYSTAL-1 trial.
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected Data
Alberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Frontline Trifluridine and Tipiracil Plus Bevacizumab Matches Efficacy of Capecitabine-Bevacizumab Combo in Metastatic Colon CancerDecember 22nd 2022
The findings, according to a third-party expert, suggest there’s no benefit to the use of trifluridine and tipiracil alone in earlier lines of therapy for the treatment of colon cancer.
The MOUNTAINEER Trial of Tucatinib for Treatment of HER2+ mCRCDecember 21st 2022
John Strickler, MD, details the design and outcomes of the MOUNTAINEER trial investigating the combination treatment of tucatinib with trastuzumab for HER2+ metastatic colorectal cancer.
Emerging Targets in the Treatment of Metastatic Colorectal CancerDecember 21st 2022
A panel of expert oncologists discusses advances in the treatment of BRAFV600E metastatic colorectal cancer and also reviews novel targets being investigated in the setting of metastatic colorectal cancer.
Toxicity Management with Trastuzumab Deruxtecan in HER2+ Metastatic Colorectal CancerDecember 21st 2022
Deanna Griffie, MSN, AGNP-BC, shares how common toxicities in patients with HER2+ mCRC being treated with trastuzumab deruxtecan are treated at her clinic.
FDA Approves New Dosing Regimens, Indications for Capecitabine Across Multiple Cancer TypesDecember 15th 2022
The FDA’s approval of new indications and dosing regimens of capecitabine across several cancer types, including breast cancer and colon cancer, marks the first drug to receive an update under the agency’s Project Renewal program.
Appropriate Patient Selection for Patients with HER2+ Metastatic Colorectal Cancer for Anti-HER2 TherapiesDecember 14th 2022
Dr Tanios Bekaii-Saab describes for which patient groups he would use anti-HER2 therapies as a second-line treatment for HER2+ metastatic colorectal cancer.
MOUNTAINEER Study: Tucatinib in Patients With HER2-Positive Metastatic CRCDecember 14th 2022
Expert panelists review data from the MOUNTAINEER study, which tested tucatinib alone or in combination with trastuzumab in patients with metastatic colorectal cancer.
A Patient’s Treatment Journey with HER2+ Metastatic Colorectal CancerDecember 14th 2022
Patient Elle Charnisky shares her experience with a conventional chemotherapy treatment for her HER2+ metastatic colorectal cancer before transitioning to targeted therapies.
DESTINY-CRC01: Role of Trastuzumab Deruxtecan in HER2-Positive Metastatic CRCDecember 14th 2022
Shared perspective on the use of trastuzumab deruxtecan in HER2+ metastatic colorectal cancer following results from the DESTINY-CRC01 trial.
First-Line Treatment Options for HER2+ Metastatic Colorectal CancerDecember 7th 2022
Dr Bekaii-Saab provides an overview of the first-line treatment options in metastatic colorectal cancer, and the factors that impact treatment decision-making.
Barriers to Molecular Testing in Metastatic Colorectal CancerDecember 7th 2022
Tanios Bekaii-Saab, MD, explains the barriers to molecular testing for patients with metastatic colorectal cancer, and how they can be addressed.
Overview of HER2-Positive Metastatic CRCDecember 7th 2022
A panel of expert oncologists consider how HER2 expression can positively impact the selection of targeted therapies for patients with metastatic colorectal cancer.
PARADIGM Trial: Panitumumab in RAS Wild-Type and Left-Sided Metastatic CRCDecember 7th 2022
Expert perspectives on the PARADIGM study, which highlighted the role of panitumumab in combination with frontline chemotherapy in patients with left-sided, RAS wild-type metastatic colorectal cancer.